Southern Hemisphere vaccine JA_Redacted.pdf

PDF 151 KB Posted

Attached to
2023 Southern Hemisphere Influenza Vaccine
Solicitation number
SPE2DP22R0005
Issued by

About this file

This document is a justification for a sole source contract award. The Defense Logistics Agency Troop Support Medical intends to award a one-year firm fixed price contract to Sanofi Pasteur Inc. for 6,000 packages of the Southern Hemisphere Influenza Vaccine, totaling 60,000 doses. The estimated unit price and maximum contract value are redacted. This vaccine is necessary for populations in the Southern Hemisphere, where the influenza season runs from April through September. A sources sought notice published on July 1st received only one response on July 7th from Sanofi Pasteur. Market research indicates Sanofi Pasteur is the only approved manufacturer of this vaccine in the US. The contract was awarded to an unknown vendor for an unknown amount on November 3rd, 2022.

View the file

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Source Selection Information - FAR 2.101 and 3.104

Justification for Other than Full and Open Competition In accordance with 10 US 2304 (c)(1)

1. Defense Logistics Agency (DLA) Troop Support, Medical Supply Chain, is the contracting activity.

2. The action being approved is the ability to solicit for DLA requirements on an other than full and open competition basis.

3. The proposed acquisition will result in a one (1) year firm fixed price definite quantity contract for the Southern Hemisphere Influenza Vaccine. The sole source for this vaccine is Sanofi Pasteur Inc.

National Stock Number (NSN): 6505-01-701-5323 Quantity: 6,000 Packages (PG), 60,000 doses Estimated Unit Price:

Federal Excise Tax (FET):

Estimated Dollar Value:

Maximum Dollar Value:

The quantity is based on the requirements received from the Services.

4. The applicable statutory authority permitting other than full and open competition is 10 U.S.C. 2304(c)(1), FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.

5. Fluzone® Quadrivalent Southern Hemisphere is a vaccine indicated for active immunization for the prevention of the influenza virus. Fluzone® Quadrivalent Southern Hemisphere is approved for use in persons six (6) months of age and older. For the 2023-2024 flu season, Sanofi Pasteur has United States Food and Drug Administration (FDA) approval to market a quadrivalent flu vaccine, which means it includes four (4) different strains of the flu virus. Multiple strains of influenza virus circulate in the population every year and the immune response is different to each of these strains, so an effective vaccine gives protection against each. The Southern Hemisphere Influenza Vaccine is considered necessary for the sector of the population that is located in the Southern Hemisphere, where the Influenza season runs from April through September.

6. In accordance with FAR 5.2, this requirement will be synopsized on Sam.gov. In addition, this justification will be made available for public inspection, after award, in accordance with

WESOLOWSKI.JENN Digitally signed by

WESOLOWSKI.JENNA.LYNN.1364

A.LYNN.1364950256 950256

Date: 2022.09.14 10:03:01 -04'00'

FAR.6.305(a). This procurement is being solicited under a specification with essential characteristics.

7. As the Contracting Officer, I hereby determine that the anticipated cost to the Government will be fair and reasonable based on an analysis of other than cost and pricing data.

8. Market research indicates that Sanofi Pasteur is the only FDA approved manufacturer of the Southern Hemisphere Flu vaccine sold in the US. As part of market research, a Sources Sought Notice was posted on www.SAM.gov on July 1, 2022 for thirty (30) days, in an attempt to find alternate sources for the vaccine, and also to investigate if alternate sources are currently being developed. The SSN closed on August 1, 2022, with only one response received from Sanofi Pasteur on July 7, 2022. DLA Troop Support, in conjunction with The Defense Health Agency Immunization Healthcare Division (DHA-IHD) at Falls Church, VA will continue to perform market research prior to any future acquisitions for the requirement.

9. There are no other facts supporting the use of Other Than Full and Open Competition.

10. The only known source for the supply of Southern Hemisphere Influenza Virus Vaccine in the US is Sanofi Pasteur, Swiftwater, Pennsylvania, which has expressed interest in fulfilling the Government’s requirements for this type of vaccine.

11.

In an effort to foster competition, however, the Government has produced a specification with essential characteristics and will advertise the requirements as stated in paragraph six (6) above. In accordance with FAR 6.302- 1(d)(2), any proposal in response to this notice will be considered.

12. The undersigned Contracting Officer hereby certifies that the information contained in this justification is accurate and complete to the best of her knowledge and belief.

Date JENNA WESOLOWSKI Contracting Officer http://www.sam.gov/

I hereby certify that the requirements which form the basis of this justification are accurate, that these supplies meet the Government’s needs in accordance with applicable specifications and that this justification is accurate and complete to the best of my knowledge and belief.

Date

I have reviewed this justification and recommend approval.

I have reviewed this justification for legal sufficiency.

File details come from the government source that posted it. Updated .